BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27744327)

  • 1. Changes in the availability and affordability of subsidised artemisinin combination therapy in the private drug retail sector in rural Ghana: before and after the introduction of the AMFm subsidy.
    Ansah EK; Whitty CJ; Bart-Plange C; Gyapong M
    Int Health; 2016 Nov; 8(6):427-432. PubMed ID: 27744327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries.
    Davis B; Ladner J; Sams K; Tekinturhan E; de Korte D; Saba J
    Malar J; 2013 Apr; 12():135. PubMed ID: 23607504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subsidising artemisinin-based combination therapy in the private retail sector.
    Opiyo N; Yamey G; Garner P
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009926. PubMed ID: 26954551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in availability and prices of subsidized ACT over the first year of the AMFm: evidence from remote regions of Tanzania.
    Yadav P; Cohen JL; Alphs S; Arkedis J; Larson PS; Massaga J; Sabot O
    Malar J; 2012 Aug; 11():299. PubMed ID: 22929587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data.
    Tougher S; ; Ye Y; Amuasi JH; Kourgueni IA; Thomson R; Goodman C; Mann AG; Ren R; Willey BA; Adegoke CA; Amin A; Ansong D; Bruxvoort K; Diallo DA; Diap G; Festo C; Johanes B; Juma E; Kalolella A; Malam O; Mberu B; Ndiaye S; Nguah SB; Seydou M; Taylor M; Rueda ST; Wamukoya M; Arnold F; Hanson K
    Lancet; 2012 Dec; 380(9857):1916-26. PubMed ID: 23122217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism.
    ; Tougher S; Hanson K; Goodman C
    Malar J; 2017 Apr; 16(1):173. PubMed ID: 28441956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme.
    Smith N; Obala A; Simiyu C; Menya D; Khwa-Otsyula B; O'Meara WP
    Malar J; 2011 Oct; 10():316. PubMed ID: 22029829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do price subsidies on artemisinin combination therapy for malaria increase household use? Evidence from a repeated cross-sectional study in remote regions of Tanzania.
    Cohen JL; Yadav P; Moucheraud C; Alphs S; Larson PS; Arkedis J; Massaga J; Sabot O
    PLoS One; 2013; 8(7):e70713. PubMed ID: 23923018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Has Tanzania embraced the green leaf? Results from outlet and household surveys before and after implementation of the Affordable Medicines Facility-malaria.
    Thomson R; Festo C; Johanes B; Kalolella A; Bruxvoort K; Nchimbi H; Tougher S; Cairns M; Taylor M; Kleinschmidt I; Ye Y; Mann A; Ren R; Willey B; Arnold F; Hanson K; Kachur SP; Goodman C
    PLoS One; 2014; 9(5):e95607. PubMed ID: 24816649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing availability, prices, and market share of quality-assured malaria ACT and RDT in the private retail sector in Nigeria and Uganda.
    Woldeghebriel M; Aso E; Berlin E; Fashanu C; Kirumira SN; Lam F; Mugerwa R; Nakiganda J; Olaleye T; Opigo J; Osinupebi F; Priestley N; Stringham R; Uhomoibhi P; Visser T; Ward A; Wiwa O; Woolsey A
    Malar J; 2024 Feb; 23(1):41. PubMed ID: 38321459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Affordable Medicines Facility-malaria (AMFm): are remote areas benefiting from the intervention?
    Ye Y; Arnold F; Noor A; Wamukoya M; Amuasi J; Blay S; Mberu B; Ren R; Kyobutungi C; Wekesah F; Gatakaa H; Toda M; Njogu J; Evance I; O'Connell K; Shewchuk T; Thougher S; Mann A; Willey B; Goodman C; Hanson K
    Malar J; 2015 Oct; 14():398. PubMed ID: 26452625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania.
    Sabot OJ; Mwita A; Cohen JM; Ipuge Y; Gordon M; Bishop D; Odhiambo M; Ward L; Goodman C
    PLoS One; 2009 Sep; 4(9):e6857. PubMed ID: 19724644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of the Affordable Medicines for Malaria Facility (AMFm) in Ghana: processes, challenges and achievements.
    Malm KL; Segbaya S; Forson I; Gakpey KD; Sampong LB; Adjei EA; Bart-Plange C
    J Public Health Policy; 2013 May; 34(2):302-14. PubMed ID: 23575513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in access to malaria treatment in Tanzania after switch to artemisinin combination therapy and the introduction of accredited drug dispensing outlets - a provider perspective.
    Alba S; Hetzel MW; Goodman C; Dillip A; Liana J; Mshinda H; Lengeler C
    Malar J; 2010 Jun; 9():164. PubMed ID: 20550654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the Affordable Medicines Facility-malaria in Ghana: the role of caregivers and licensed chemical sellers in four regions.
    Adjei AA; Winch P; Laar A; Sullivan DJ; Sakyi KS; Stephens JK; Adjei GO; Boateng IA; Aubyn VN; Kubio C; Tuakli J; Vanotoo L; Bortei BB; Amo-Addae M; Sorvor F; Coleman N; Dalglish S; Owusu R; Gebreyesus T; Essuman E; Greene R; Ankomah E; Houston K; Bart-Plange C; Salamat S; Addison EA; Quakyi IA
    Malar J; 2016 May; 15(1):263. PubMed ID: 27160685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries.
    O'Connell KA; Gatakaa H; Poyer S; Njogu J; Evance I; Munroe E; Solomon T; Goodman C; Hanson K; Zinsou C; Akulayi L; Raharinjatovo J; Arogundade E; Buyungo P; Mpasela F; Adjibabi CB; Agbango JA; Ramarosandratana BF; Coker B; Rubahika D; Hamainza B; Chapman S; Shewchuk T; Chavasse D
    Malar J; 2011 Oct; 10():326. PubMed ID: 22039838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two years post affordable medicines facility for malaria program: availability and prices of anti-malarial drugs in central Ghana.
    Freeman A; Kwarteng A; Febir LG; Amenga-Etego S; Owusu-Agyei S; Asante KP
    J Pharm Policy Pract; 2017; 10():15. PubMed ID: 28465829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards subsidized malaria rapid diagnostic tests. Lessons learned from programmes to subsidise artemisinin-based combination therapies in the private sector: a review.
    Lussiana C
    Health Policy Plan; 2016 Sep; 31(7):928-39. PubMed ID: 25862732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cross-sectional study of the availability and price of anti-malarial medicines and malaria rapid diagnostic tests in private sector retail drug outlets in rural Western Kenya, 2013.
    Kioko U; Riley C; Dellicour S; Were V; Ouma P; Gutman J; Kariuki S; Omar A; Desai M; Buff AM
    Malar J; 2016 Jul; 15(1):359. PubMed ID: 27406179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of introducing subsidized combination treatment with artemether-lumefantrine on sales of anti-malarial monotherapies: a survey of private sector pharmacies in Huambo, Angola.
    Lussiana C; Floridia M; Martinho do Rosário J; Fortes F; Allan R
    Trans R Soc Trop Med Hyg; 2016 Dec; 110(10):588-596. PubMed ID: 27856948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.